<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35188021</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nanocrystals based pulmonary inhalation delivery system: advance and challenge.</ArticleTitle>
        <Pagination>
          <StartPage>637</StartPage>
          <EndPage>651</EndPage>
          <MedlinePgn>637-651</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2039809</ELocationID>
        <Abstract>
          <AbstractText>Pulmonary inhalation administration is an ideal approach to locally treat lung disease and to achieve systemic administration for other diseases. However, the complex nature of the structural characteristics of the lungs often results in the difficulty in the development of lung inhalation preparations. Nanocrystals technology provides a potential formulation strategy for the pulmonary delivery of poorly soluble drugs, owing to the decreased particle size of drug, which is a potential approach to overcome the physiological barrier existing in the lungs and significantly increased bioavailability of drugs. The pulmonary inhalation administration has attracted considerable attentions in recent years. This review discusses the barriers for pulmonary drug delivery and the recent advance of the nanocrystals in pulmonary inhalation delivery. The presence of nanocrystals opens up new prospects for the development of novel pulmonary delivery system. The particle size control, physical instability, potential cytotoxicity, and clearance mechanism of inhaled nanocrystals based formulations are the major considerations in formulation development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yue</LastName>
            <ForeName>Pengfei</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Weicheng</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Guiting</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Fangfang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yingchong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Zhilin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Langka Biotechnology (Shanghai) Co., Ltd, Shanghai, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Liru</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Beijing Hospital, Beijing, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011663">Pulmonary Surfactants</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005612" MajorTopicYN="N">Freeze Drying</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016676" MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011663" MajorTopicYN="N">Pulmonary Surfactants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Nanocrystals</Keyword>
        <Keyword MajorTopicYN="N">bioavailability</Keyword>
        <Keyword MajorTopicYN="N">lungs</Keyword>
        <Keyword MajorTopicYN="N">physiological barrier</Keyword>
        <Keyword MajorTopicYN="N">pulmonary inhalation administration</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was declared by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>8</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35188021</ArticleId>
        <ArticleId IdType="pmc">PMC8865109</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2039809</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abd Elwakil MM, Mabrouk MT, Helmy MW, et al.  (2018). Inhalable lactoferrin–chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma. Nanomedicine
13:2015–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30191764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdelbary AA, Al-Mahallawi AM, Abdelrahim ME, et al.  (2015). Preparation, optimization, and in vitro simulated inhalation delivery of carvedilol nanoparticles loaded on a coarse carrier intended for pulmonary administration. Int J Nanomedicine
10:6339–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4608592</ArticleId>
            <ArticleId IdType="pubmed">26491298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alblas ABvO, Linden-Schrever B, Furth R. (1981). Origin and kinetics of pulmonary macrophages during an inflammatory reaction induced by intravenous administration of heat-killed bacillus Calmette–Guérin. J Exp Med
154:235–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2186414</ArticleId>
            <ArticleId IdType="pubmed">7264558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alhajj N, O'Reilly NJ, Cathcart H. (2021). Designing enhanced spray dried particles for inhalation: a review of the impact of excipients and processing parameters on particle properties. Powder Technol
384:313–31.</Citation>
        </Reference>
        <Reference>
          <Citation>Ali H, York P, Ali A, et al.  (2011). Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release
149:175–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20946923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Obaidi H, Granger A, Hibbard T, et al.  (2021). Pulmonary drug delivery of antimicrobials and anticancer drugs using solid dispersions. Pharmaceutics
13:1056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8309119</ArticleId>
            <ArticleId IdType="pubmed">34371747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araújo F, Martins C, Azevedo C, et al.  (2018). Chemical modification of drug molecules as strategy to reduce interactions with mucus. Adv Drug Deliv Rev
124:98–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28964880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arick DQ, Choi YH, Kim HC, et al.  (2015). Effects of nanoparticles on the mechanical functioning of the lung. Adv Colloid Interface Sci
225:218–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26494653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bansil R, Turner BS. (2006). Mucin structure, aggregation, physiological functions and biomedical applications. Curr Opin Colloid Interface Sci
11:164–70.</Citation>
        </Reference>
        <Reference>
          <Citation>Basu A, Guti S, Kundu S, et al.  (2020). Oral andrographolide nanocrystals protect liver from paracetamol induced injury in mice. J Drug Deliv Sci Technol
55:101406.</Citation>
        </Reference>
        <Reference>
          <Citation>Bhavna  , Ahmad FJ, Khar RK, et al.  (2009). Techniques to develop and characterize nanosized formulation for salbutamol sulfate. J Mater Sci Mater Med
20:S71–S6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18543087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Button B, Cai LH, Ehre C, et al.  (2012). A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science
337:937–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3633213</ArticleId>
            <ArticleId IdType="pubmed">22923574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang D, Ma Y, Cao G, et al.  (2018). Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol
46:1018–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28749189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Gui Y, Luo Y, et al.  (2021). Design and evaluation of inhalable nanocrystals embedded microparticles with enhanced redispersibility and bioavailability for breviscapine. Powder Technol
377:128–38.</Citation>
        </Reference>
        <Reference>
          <Citation>Chiang PC, Alsup JW, Lai Y, et al.  (2009). Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res Lett
4:254–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2894320</ArticleId>
            <ArticleId IdType="pubmed">20596335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cipolla D, Wu H, Eastman S, et al.  (2016). Tuning ciprofloxacin release profiles from liposomally encapsulated nanocrystalline drug. Pharm Res
33:2748–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5040743</ArticleId>
            <ArticleId IdType="pubmed">27439506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costabile G, D’Angelo I, Rampioni G, et al.  (2015). Toward repositioning niclosamide for antivirulence therapy of Pseudomonas aeruginosa lung infections: development of inhalable formulations through nanosuspension technology. Mol Pharm
12:237–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25974285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costabile G, Provenzano R, Azzalin A, et al.  (2020). PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection. Nanomedicine
23:102113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31669084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Kruijf W, Ehrhardt C. (2017). Inhalation delivery of complex drugs—the next steps. Curr Opin Pharmacol
36:52–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28846876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding J, Takamoto DY, von Nahmen A, et al.  (2001). Effects of lung surfactant proteins, SP-B and SP-C, and palmitic acid on monolayer stability. Biophys J
80:2262–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1301417</ArticleId>
            <ArticleId IdType="pubmed">11325728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du J, Li X, Zhao H, et al.  (2015). Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies. Int J Pharm
495:738–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26383838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duggirala NK, Perry ML, Almarsson O, et al.  (2016). Pharmaceutical cocrystals: along the path to improved medicines. Chem Commun
52:640–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26565650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eerikäinen H, Watanabe W, Kauppinen EI, et al.  (2003). Aerosol flow reactor method for synthesis of drug nanoparticles. Eur J Pharm Biopharm
55:357–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12754012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Gendy N, Gorman EM, Munson EJ, et al.  (2009). Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci
98:2731–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4610389</ArticleId>
            <ArticleId IdType="pubmed">19130469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsayed I, AbouGhaly MH. (2016). Inhalable nanocomposite microparticles: preparation, characterization and factors affecting formulation. Expert Opin Drug Deliv
13:207–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26512950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsayed MMA, Shalash AO. (2018). Modeling the performance of carrier-based dry powder inhalation formulations: where are we, and how to get there?
J Control Release
279:251–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29574042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao L, Zhang D, Chen M. (2008). Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res
10:845–62.</Citation>
        </Reference>
        <Reference>
          <Citation>Gao L, Liu G, Ma J, et al.  (2012). Drug nanocrystals: in vivo performances. J Control Release
160:418–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22465393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Díaz M, Birch D, Wan F, et al.  (2018). The role of mucus as an invisible cloak to transepithelial drug delivery by nanoparticles. Adv Drug Deliv Rev
124:107–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29117511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goerke J. (1998). Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta
1408:79–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9813251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonda I. (2006). Systemic delivery of drugs to humans via inhalation. J Aerosol Med
19:47–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16551214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Liang Y, Mak JCW, et al.  (2020). Size effect of curcumin nanocrystals on dissolution, airway mucosa penetration, lung tissue distribution and absorption by pulmonary delivery. Colloids Surf B Biointerfaces
186:110703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31835185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu G, Jiao B, Shi X, et al.  (2013). Physicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein corona. ACS Nano
7:10525–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5362675</ArticleId>
            <ArticleId IdType="pubmed">24266809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang G, Xie J, Shuai S, et al.  (2021). Nose-to-brain delivery of drug nanocrystals by using Ca2+ responsive deacetylated gellan gum based in situ-nanogel. Int J Pharm
594:120182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33346126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jakubowska E, Lulek J. (2021). The application of freeze-drying as a production method of drug nanocrystals and solid dispersions—a review. J Drug Deliv Sci Technol
62:102357.</Citation>
        </Reference>
        <Reference>
          <Citation>Jermain SV, Brough C, Williams RO. (2018). Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery – an update. Int J Pharm
535:379–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29128423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson M, Bao H, Helms M, et al.  (2006). Functional ion channels in pulmonary alveolar type I cells support a role for type I cells in lung ion transport. Proc Natl Acad Sci U S A
103:4964–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1458778</ArticleId>
            <ArticleId IdType="pubmed">16549766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kannan R, Xu Q, Kambhampati S. (2013). Nanotechnology approaches for ocular drug delivery. Middle East Afr J Ophthalmol
20:26–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3617524</ArticleId>
            <ArticleId IdType="pubmed">23580849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kraft WK, Steiger B, Beussink D, et al.  (2004). The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol
44:67–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14681343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laaksonen T, Liu P, Rahikkala A, et al.  (2011). Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods. Pharm Res
28:2403–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21537875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee WH, Loo CY, Traini D, et al.  (2015). Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opin Drug Deliv
12:1009–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25912721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei Y, Kong Y, Sui H, et al.  (2016). Enhanced oral bioavailability of glycyrrhetinic acid via nanocrystal formulation. Drug Deliv Transl Res
6:519–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27206446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Wang D, Lu S, et al.  (2018). Pramipexole nanocrystals for transdermal permeation: characterization and its enhancement micro-mechanism. Eur J Pharm Sci
124:80–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30076954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao Q, Yip L, Chow MYT, et al.  (2019). Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition. Int J Pharm
560:144–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30731259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling X, Shen Y, Sun CM, et al.  (2014). Current progress on pulmonary drug delivery. J Pharm Res
33:711–3.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Q, Guan J, Qin L, et al.  (2020). Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discov Today
25:150–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31600580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Guan J, Sun Z, et al.  (2019). Influence of stabilizer type and concentration on the lung deposition and retention of resveratrol nanosuspension-in-microparticles. Int J Pharm
569:118562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31351178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Han M, Tian F, et al.  (2018). Budesonide nanocrystal-loaded hyaluronic acid microparticles for inhalation: in vitro and in vivo evaluation. Carbohydr Polym
181:1143–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29253943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, Yao G, Zhang X, et al.  (2018). Systematical investigation of different drug nanocrystal technologies to produce fast dissolving meloxicam tablets. AAPS PharmSciTech
19:783–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29019059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Liu W, Xiong S, et al.  (2020). Highly stabilized nanocrystals delivering ginkgolide B in protecting against the Parkinson's disease. Int J Pharm
577:119053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31981707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loira-Pastoriza C, Todoroff J, Vanbever R. (2014). Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev
75:81–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24915637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y, Zhao D, Li N, et al.  (2018). Research advances of controlled release formulations for pulmonary delivery. J Pharm Res
37:469–72.</Citation>
        </Reference>
        <Reference>
          <Citation>Luo Y, Zhang Z, Huang G, et al.  (2020). Roles of maltodextrin and inulin as matrix formers on particle performance of inhalable drug nanocrystal-embedded microparticles. Carbohydr Polym
235:115937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32122479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malamatari M, Taylor KMG, Malamataris S, et al.  (2018). Pharmaceutical nanocrystals: production by wet milling and applications. Drug Discov Today
23:534–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29326082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manca ML, Lai F, Pireddu R, et al.  (2020). Impact of nanosizing on dermal delivery and antioxidant activity of quercetin nanocrystals. J Drug Deliv Sci Technol
55:101482.</Citation>
        </Reference>
        <Reference>
          <Citation>Mangal S, Gao W, Li T, et al.  (2017). Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol Sin
38:782–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5520191</ArticleId>
            <ArticleId IdType="pubmed">28504252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mansour HM, Rhee YS, Wu X. (2009). Nanomedicine in pulmonary delivery. Int J Nanomedicine
4:299–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2802043</ArticleId>
            <ArticleId IdType="pubmed">20054434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehanna MM, Mohyeldin SM, Elgindy NA. (2019). Rifampicin-carbohydrate spray-dried nanocomposite: a futuristic multiparticulate platform for pulmonary delivery. Int J Nanomedicine
14:9089–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6879549</ArticleId>
            <ArticleId IdType="pubmed">31819421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller R, Shegokar R, Gohla S, et al.  (2011). Nanocrystals: production, cellular drug delivery, current and future products. Fundam Biomed Technol
5:411–32.</Citation>
        </Reference>
        <Reference>
          <Citation>Muralidharan P, Malapit M, Mallory E, et al.  (2015). Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine
11:1189–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25659645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni R, Zhao J, Liu Q, et al.  (2017). Nanocrystals embedded in chitosan-based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery. Eur J Pharm Sci
99:137–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27988327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberdörster G, Ferin J, Lehnert BE. (1994). Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect
102:173–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1567252</ArticleId>
            <ArticleId IdType="pubmed">7882925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberdörster G, Oberdörster E, Oberdörster J. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect
113:823–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1257642</ArticleId>
            <ArticleId IdType="pubmed">16002369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onoue S, Aoki Y, Kawabata Y, et al.  (2011). Development of inhalable nanocrystalline solid dispersion of tranilast for airway inflammatory diseases. J Pharm Sci
100:622–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20653048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ordonez SR, Veldhuizen EJA, van Eijk M, et al.  (2017). Role of soluble innate effector molecules in pulmonary defense against fungal pathogens. Front Microbiol
8:2098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5671533</ArticleId>
            <ArticleId IdType="pubmed">29163395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrander KD, Bosch HW, Bondanza DM. (1999). An in-vitro assessment of a NANOCRYSTAL beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm
48:207–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10612031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patton JS, Byron PR. (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov
6:67–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17195033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawar VK, Singh Y, Meher JG, et al.  (2014). Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release
183:51–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24667572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelikh O, Eckert RW, Pinnapireddy SR, et al.  (2021). Hair follicle targeting with curcumin nanocrystals: influence of the formulation properties on the penetration efficacy. J Control Release
329:598–613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33011240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Gil J, Weaver TE. (2010). Pulmonary surfactant pathophysiology: current models and open questions. Physiology
25:132–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20551227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pomázi A, Buttini F, Ambrus R, et al.  (2013). Effect of polymers for aerosolization properties of mannitol-based microcomposites containing meloxicam. Eur Polym J
49:2518–27.</Citation>
        </Reference>
        <Reference>
          <Citation>Praphakar RA, Shakila H, Azger Dusthackeer VN, et al.  (2018). A mannose-conjugated multi-layered polymeric nanocarrier system for controlled and targeted release on alveolar macrophages. Polym Chem
9:668.</Citation>
        </Reference>
        <Reference>
          <Citation>Raula J, Rahikkala A, Halkola T, et al.  (2013). Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate. Int J Pharm
441:248–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23200957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roa WH, Azarmi S, Al-Hallak MH, et al.  (2011). Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release
150:49–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21059378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogueda PG, Traini D. (2007). The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin Drug Deliv
4:595–606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17970663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi I, Sonvico F, McConville JT, et al.  (2018). Nebulized coenzyme Q10 nanosuspensions: a versatile approach for pulmonary antioxidant therapy. Eur J Pharm Sci
113:159–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29066385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rouse JJ, Whateley TL, Thomas M, et al.  (2007). Controlled drug delivery to the lung: influence of hyaluronic acid solution conformation on its adsorption to hydrophobic drug particles. Int J Pharm
330:175–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17207592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rundfeldt C, Steckel H, Scherliess H, et al.  (2013). Inhalable highly concentrated itraconazole nanosuspension for the treatment of bronchopulmonary aspergillosis. Eur J Pharm Biopharm
83:44–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23064325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders N, Rudolph C, Braeckmans K, et al.  (2009). Extracellular barriers in respiratory gene therapy. Adv Drug Deliv Rev
61:115–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7103358</ArticleId>
            <ArticleId IdType="pubmed">19146894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirley M. (2019). Amikacin liposome inhalation suspension: a review in Mycobacterium avium complex lung disease. Drugs
79:555–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6445814</ArticleId>
            <ArticleId IdType="pubmed">30877642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha B, Müller RH, Möschwitzer JP. (2013). Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm
453:126–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23333709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siow CR, Wan Sia Heng P, Chan LW. (2016). Application of freeze-drying in the development of oral drug delivery systems. Expert Opin Drug Deliv
13:1595–608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27267745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O' Donnell KP, Smyth HDC. (2011). Macro- and microstructure of the airways for drug delivery. In: Smyth H, Hickey A, eds. Controlled pulmonary drug delivery. Advances in Delivery Science and Technology. Springer, New York, NY, 1–19.</Citation>
        </Reference>
        <Reference>
          <Citation>Song S, Guo J, Li H. (2013). Preparation of a high-efficiency nebulizer of betamethasone dipropionate by high pressure microfluidization. Journal of Controlled Release 172:e66.</Citation>
        </Reference>
        <Reference>
          <Citation>Sou T, Orlando L, McIntosh MP, et al.  (2011). Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int J Pharm
421:220–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21963471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung JC, Pulliam BL, Edwards DA. (2007). Nanoparticles for drug delivery to the lungs. Trends Biotechnol
25:563–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17997181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka R, Hattori Y, Otsuka M, et al.  (2020). Application of spray freeze drying to theophylline–oxalic acid cocrystal engineering for inhaled dry powder technology. Drug Dev Ind Pharm
46:179–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31937148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao L, Müller R, Mschwitzer JP. (2016). Systematical investigation of a combinative particle size reduction technology for production of resveratrol nanosuspensions. AAPS PharmSciTech
18:1–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27696301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thakkar S, Shah V, Misra M, et al.  (2017). Nanocrystal based drug delivery system: conventional and current scenario. Recent Pat Nanotechnol
11:130–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27758683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torvela T, Lähde A, Mönkäre J, et al.  (2011). Low-temperature aerosol flow reactor method for preparation of surface stabilized pharmaceutical nanocarriers. J Aerosol Sci
42:645–56.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang J, Yang Y, Yu M, et al.  (2018). Diffusion of rod-like nanoparticles in non-adhesive and adhesive porous polymeric gels. J Mech Phys Solids
112:431–57.</Citation>
        </Reference>
        <Reference>
          <Citation>Wei S, Xie J, Luo Y, et al.  (2018). Hyaluronic acid based nanocrystals hydrogels for enhanced topical delivery of drug: a case study. Carbohydr Polym
202:64–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30287044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whitsett JA, Weaver TE. (2002). Hydrophobic surfactant proteins in lung function and disease. N Engl J Med
347:2141–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12501227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wüstneck R, Perez-Gil J, Wüstneck N, et al.  (2005). Interfacial properties of pulmonary surfactant layers. Adv Colloid Interface Sci
117:33–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16120435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing Y, Lu P, Xue Z, et al.  (2020). Nano-strategies for improving the bioavailability of inhaled pharmaceutical formulations. Mini Rev Med Chem
20:1258–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32386491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong S, Liu W, Zhou Y, et al.  (2020). Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation. Asian J Pharm Sci
15:518–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7486547</ArticleId>
            <ArticleId IdType="pubmed">32952674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamasaki K, Kwok PC, Fukushige K, et al.  (2011). Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int J Pharm
420:34–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21864662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang MY, Chan JG, Chan HK. (2014). Pulmonary drug delivery by powder aerosols. J Control Release
193:228–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24818765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Johnston KP, Williams RO 3rd. (2010). Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm
75:33–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20102737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Peters JI, Williams RO. (2008). Inhaled nanoparticles—a current review. Int J Pharm
356:239–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18358652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Q, Wu X, Zhu Q, et al.  (2018). Enhanced transdermal delivery of meloxicam by nanocrystals: preparation, in vitro and in vivo evaluation. Asian J Pharm Sci
13:518–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7032118</ArticleId>
            <ArticleId IdType="pubmed">32104426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu SH, Possmayer F. (2003). Lipid compositional analysis of pulmonary surfactant monolayers and monolayer-associated reservoirs. J Lipid Res
44:621–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12562850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue PF, Liu Y, Xie J, et al.  (2018). Review and prospect on preparation technology of drug nanocrystals in the past thirty years. Acta Pharm Sin B
53:529–37.</Citation>
        </Reference>
        <Reference>
          <Citation>Zheng JY, Bosch HW. (1997). Sterile filtration of nanocrystal drug formulations. Drug Dev Ind Pharm
23:1087–93.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
